Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners

被引：26

作者：

Chaisson, RE ^{[1
]}

Armstrong, J

Stafford, J

Golub, J

Bur, S

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA

[2] Maryland Dept Publ Safety & Correct Serv, Towson, MD USA

[3] Baltimore Washington Int Airport, Maryland Dept Publ Transportat, Baltimore, MD 21240 USA

[4] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2002年 / 288卷 / 02期

关键词：

D O I：

10.1001/jama.288.2.165

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：165 / 166

页数：2

共 5 条

[1]

[Anonymous], AM J RESP CRIT CARE

[2] Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates [J].

Bock, NN ;

Rogers, T ;

Tapia, JR ;

Herron, GD ;

DeVoe, B ;

Geiter, LJ .

CHEST, 2001, 119 (03) :833-837

[3] Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons - An international randomized trial [J].

Gordin, F ;

Chaisson, RE ;

Matts, JP ;

Miller, C ;

Garcia, MD ;

Hafner, R ;

Valdespino, JL ;

Coberly, J ;

Schechter, M ;

Klukowicz, AJ ;

Barry, MA ;

O'Brien, RJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (11) :1445-1450

[4] Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection [J].

Halsey, NA ;

Coberly, JS ;

Desormeaux, J ;

Losikoff, P ;

Atkinson, J ;

Moulton, LH ;

Contave, M ;

Johnson, M ;

Davis, H ;

Geiter, L ;

Johnson, E ;

Huebner, R ;

Boulos, R ;

Chaisson, RE .

LANCET, 1998, 351 (9105) :786-792

[5]

*US CDCP, 2001, MMWR-MORBID MORTAL W, V50, P733

← 1 →